MDM2 and Human Malignancies: Expression, Clinical Pathology, Prognostic Markers, and Implications for Chemotherapy
The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.
Abstract
The human homologue of the mouse double minute 2 (MDM2) oncogene is overexpressed in more than forty different types of malignancies, including solid tumors, sarcomas and leukemias. Because of its prevalent expression and its interactions with p53 and other signaling molecules, MDM2 plays a central role in cancer development and progression. The expression of this oncoprotein is being studied by researchers world-wide, and the amount of data published about it is increasing exponentially. Although there are some conflicting data about the effects of MDM2 expression in individual cancers, the overall evidence is convincing, indicating that increased MDM2 expression is related to a worse clinical prognosis. There is an increased likelihood of distant metastases, as well as a decreased response to therapeutic intervention in MDM2-positive cancers. MDM2 may also serve as a diagnostic marker, not only for cancer stage, but to differentiate between similar cancers. MDM2 may also be associated with drug resistance in cancer chemotherapy. These findings make studying the oncoprotein necessary to aid in our understanding of cancer development, to identify novel cancer drug targets, and to increase the efficacy of cancer therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overexpression of Mdm2 is frequently observed in human and murine malignancies (15, 34, 39).”
From Mdm2 Promotes Genetic Instability and Transformation Independent of p53 (2008) · cites this paper as [39]
In the citing paper
“However, MDM2 protein is elevated in 45%–75% of GBM biopsy samples”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [29]
In the citing paper
“Mdm2 is a multi-faceted protein involved in numerous aspects of cell growth, survival, and invasion (6).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [6]
In the citing paper
“In breast cancers, studies have shown Mdm2 gene amplifications range from 10–60% with some studies indicating a worse prognosis with overexpression of Mdm2 or gene amplification (6, 8).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [6]
In the citing paper
“In breast cancers, studies have shown Mdm2 gene amplifications range from 10–60% with some studies indicating a worse prognosis with overexpression of Mdm2 or gene amplification (6, 8).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [6]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“Another group studying neuroblastoma cells documented that loss of p53, including loss by MDM2- induced degradation, resulted in high-level drug resistance to melphalan (L-PAM) [91]. cancers, where HER-2 is overexpressed in an estimated 30% of tumors [97].”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605 · cited 2×
“Another group found that MDM2 was associated with an increase in expression of vascular endothelial growth factor (VEGF), which is known to promote tumor growth and metastasis [10] [66] [67] [68].”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949 · cited 1×
“…Uterine sarcoma 50% 33% No correlation 12 [190] Angiosarcoma (vascular) 68% Maybe worse 19 [9] Intimal Sarcoma (pulmonary artery) 75% Maybe worse 8 [195] Sarcoma (various) >33% n/a 47 [194] Sarcoma (various) 8% n/a 40 [8] Sarcoma 10% Worse 30 [64] Synovial sarcoma 59% n/a 49 [196] Blood cell…”
Takahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R., & Ellis, L. M. (1995) · PubMed · Cited by 1,265
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167 · cited 1×
“MDM2 and p14 have a direct interaction, which inhibits the MDM2-induced degradation of p53 [125] [126].”
BackgroundThe MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation
Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-973 · Cited by 951
Heise, C., Sampson-Johannes, A., Williams, A., Mccormick, F., Von Hoff, D. D., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 940
Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724
Fakharzadeh, S. S., Trusko, S. P., & George, D. L. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07676.x · Cited by 704
Interaction between the retinoblastoma protein and the oncoprotein MDM2
Xiao, Z.-X., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J., Sellers, W. R., & Livingston, D. M. (1995) · Nature · doi:10.1038/375694a0 · Cited by 587
Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E., & Collins, V. P. (1993) · PubMed · Cited by 560
Inhibition of MDM2-mediated p53 Ubiquitination and Degradation by Ribosomal Protein L5
Dai, M.-S., & Lu, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403722200 · Cited by 534 · cited 1×
“…also fulfill a negative regulatory function for other molecules, such as E2F1, pRb, p14/p19 ARF , p21, p63 and p73, ribosomal proteins, MDMX, and likely the estrogen, androgen and glucocorticoid receptors [55] [79] [99] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117].”
Background(1994) · PubMed · Cited by 509
Kurki, S., Peltonen, K., Latonen, L., Kiviharju, T. M., Ojala, P. M., Meek, D., & Laiho, M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00110-2 · Cited by 416 · cited 1×
“MDM2 expression is increased in p53 null cells as well, suggesting that the increase in MDM2 is p53-independent [132].”
BackgroundOverexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis
Jones, S. N., Hancock, A. R., Vogel, H., Donehower, L. A., & Bradley, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15608 · Cited by 386
Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations
Bardeesy, N., Falkoff, D., Petruzzi, M.-J., Nowak, N., Zabel, B., Adam, M., Aguiar, M. C., Grundy, P., Shows, T., & Pelletier, J. (1994) · Nature Genetics · doi:10.1038/ng0594-91 · Cited by 339
MDM2 suppresses p73 function without promoting p73 degradation
Zeng, X., Chen, L., Jost, C. A., Maya, R., Keller, D., Wang, X., Kaelin, W. G., Oren, M., Chen, J., & Lu, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3257 · Cited by 334
MDM2 interacts with MDMX through their RING finger domains
Tanimura, S., Ohtsuka, S., Mitsui, K., Shirouzu, K., Yoshimura, A., & Ohtsubo, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00254-9 · Cited by 324 · cited 1×
“…also fulfill a negative regulatory function for other molecules, such as E2F1, pRb, p14/p19 ARF , p21, p63 and p73, ribosomal proteins, MDMX, and likely the estrogen, androgen and glucocorticoid receptors [55] [79] [99] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117].”
BackgroundThe human MDM-2 oncogene is overexpressed in leukemias
Bueso-Ramos, C., Yang, Y., deLeon, E., McCown, P., Stass, S., & Albitar, M. (1993) · Blood · doi:10.1182/blood.v82.9.2617.2617 · Cited by 291 · cited 1×
“46% Better 93 [76] Esophageal squamous cell car.”
BackgroundDei Tos, A. P., Doglioni, C., Piccinin, S., Sciot, R., Furlanetto, A., Boiocchi, M., Dal Cin, P., Maestro, R., Fletcher, C. D. M., & Tallini, G. (2000) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(200004)190:5<531::aid-path579>3.0.co;2-w · Cited by 285
Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
Keshelava, N., Zuo, J. J., Chen, P., Waidyaratne, S. N., Luna, M. C., Gomer, C. J., Triche, T. J., & Reynolds, C. P. (2001) · PubMed · Cited by 232
Lee-Huang, S., Zhang, L., Lin Huang, P., Chang, Y.-T., & Huang, P. L. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01292-0 · Cited by 227 · cited 1×
“HIV-1 infection upregulates the expression of MDM2 [129], and anti-HIV drugs decrease its expression [130].”
BackgroundHengstermann, A., Linares, L. K., Ciechanover, A., Whitaker, N. J., & Scheffner, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1218 · Cited by 209 · cited 2×
“And SCC (penis) 18%-79% n/a 14 [137] Testicular germ cell 12% n/a 25 [18] Testicular germ cell 56%-69% Worse 32 [15] Testicular germ cell 7%-93% Worse 31 [16] Colon 65% n/a 52 [57] Colorectal 25% No correlation 52 [55] Colorectal 25% No correlation 55 [56] Melanoma 6%-56% 1% Maybe worse 172 [174]…”
BackgroundTakahashi, T., Carbone, D. P., Takahashi, T., Nau, M. M., Hida, T., Linnoila, I. R., Ueda, R., & Minna, J. D. (1992) · PubMed · Cited by 199
Altered Patterns of MDM2 and TP53 Expression in Human Bladder Cancer
Lianes, P., Orlow, I., Zhang, Z.-F., Oliva, M. R., Sarkis, A. S., Reuter, V. E., & Cordon-Cardo, C. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.17.1325 · Cited by 194
E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2.
Kowalik, T. F., DeGregori, J. V., Leone, G. W., Jakoi, L., & Nevins, J. R. (1998) · PubMed · Cited by 190
A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter
Brès, V., Kiernan, R. E., Linares, L. K., Chable-Bessia, C., Plechakova, O., Tréand, C., Emiliani, S., Peloponese, J.-M., Jeang, K.-T., Coux, O., et al. (2003) · Nature Cell Biology · doi:10.1038/ncb1023 · Cited by 184 · cited 3×
“Similar to the adverse effects of MDM2 overexpression for cancer patients, MDM2 likewise seems to be involved in the pathogenicity of HIV.”
BackgroundMDM-2 Oncoprotein Overexpression, p53 Gene Mutation, and VEGF Up-Regulation in Angiosarcomas
Zietz, C., Rössle, M., Haas, C., Sendelhofert, A., Hirschmann, A., Stürzl, M., & Löhrs, U. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65729-x · Cited by 180
Newcomb, E. W., Cohen, H., Lee, S. R., Bhalla, S. K., Bloom, J., Hayes, R. L., & Miller, D. C. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00191.x · Cited by 179 · cited 3×
“Glioblastomas and astrocytomas show positive staining for MDM2 protein in up to 75% of tumor samples, and approximately 10% of samples have gene amplification [20] [21] [22] [23] [24] [25] [26] [27] [28] [29].”
BackgroundResultIn vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.
Rogulski, K. R., Freytag, S. O., Zhang, K., Gilbert, J. D., Paielli, D. L., Kim, J. H., Heise, C. C., & Kirn, D. H. (2000) · PubMed · Cited by 178
Watanabe, T., Hotta, T., Ichikawa, A., Kinoshita, T., Nagai, H., Uchida, T., Murate, T., & Saito, H. (1994) · Blood · doi:10.1182/blood.v84.9.3158.3158 · Cited by 170
Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas
Biernat, W., Tohma, Y., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1997) · Acta Neuropathologica · doi:10.1007/s004010050711 · Cited by 166 · cited 5×
“…Brain (GBM) 33% n/a 80 [23] Brain (glioblastoma) 45%-75% Worse 89 [24] Brain (glioblastoma) 52% 7% n/a 56 [25] Brain (glioblastoma) 13% Worse 75 [26] Brain (cerebellar medulloblastoma) 20% none Maybe worse 51 [27] Brain (GBM) positive n/a 143 [28] Ependymoma 96% 35% n/a 20 [159] Intracranial…”
BackgroundInfluentialToh, Y., Oki, E., Oda, S., Tokunaga, E., Ohno, S., Maehara, Y., Nicolson, G. L., & Sugimachi, K. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970822)74:4<459::aid-ijc18>3.0.co;2-4 · Cited by 165
Blakytny, R., Jude, E. B., Martin Gibson, J., Boulton, A. J. M., & Ferguson, M. W. J. (2000) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(200004)190:5<589::aid-path553>3.0.co;2-t · Cited by 160
Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage
Chen, L., Agrawal, S., Zhou, W., Zhang, R., & Chen, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.195 · Cited by 159
Self-citationKinyamu, H. K., & Archer, T. K. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.16.5867-5881.2003 · Cited by 157 · cited 2×
“The protein may act similarly for the estrogen, androgen and glucocorticoid receptors, influencing their stability by increasing their ubiquitination [116] [117].”
BackgroundAmplification pattern of 12q13–q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer
Simon, R., Struckmann, K., Schraml, P., Wagner, U., Forster, T., Moch, H., Fijan, A., Bruderer, J., Wilber, K., Mihatsch, M. J., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205304 · Cited by 157
Gorgoulis, V. G., Zacharatos, P., Mariatos, G., Kotsinas, A., Bouda, M., Kletsas, D., Asimacopoulos, P. J., Agnantis, N., Kittas, C., & Papavassiliou, A. G. (2002) · The Journal of Pathology · doi:10.1002/path.1121 · Cited by 153
Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene
Hakobyan, N., Kazarian, T., Jabbar, A. A., Jabbar, K. J., & Valentino, L. A. (2004) · Blood · doi:10.1182/blood-2003-12-4231 · Cited by 150 · cited 1×
“…that MDM2 may be responsible for the decreased apoptosis or increased cell proliferation within the joints, causing inflammation and the debilitating effects of the resultant arthritis [138]. processes, and may allow more specific and effective treatments to be tailored to the individual cancers.”
BackgroundChêne, P., Fuchs, J. P., Bohn, J. A., García-Echeverría, C., Furet, P., & Fabbro, D. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3738 · Cited by 149
PILOTTI, S., TORRE, G. D., LAVARINO, C., PALMA, S. D., SOZZI, G., MINOLETTI, F., RAO, S., PASQUINI, G., AZZARELLI, A., RILKE, F., et al. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199701)181:1<14::aid-path730>3.0.co;2-o · Cited by 149 · cited 1×
“More than 90% of retroperitoneal liposarcomas express MDM2 protein, while less than half of non-retroperitoneal liposarcomas have an MDM2 positive phenotype, and none of the myxoid liposarcomas express the oncoprotein [139].”
BackgroundAlternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
Lukáš, J., Gao, D. Q., Keshmeshian, M., Wen, W., Tsao-Wei, D. D., Rosenberg, S. A., & Press, M. F. (2001) · PubMed · Cited by 148
APOPTOSIS OF HUMAN MONOCYTES/MACROPHAGES INMYCOBACTERIUM TUBERCULOSIS INFECTION
Placido, R., Mancino, G., Amendola, A., Mariani, F., Vendetti, S., Piacentini, M., Sanduzzi, A., Bocchino, M., Zembala, M., & Colizzi, V. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199701)181:1<67::aid-path723>3.0.co;2-z · Cited by 145
(2002) · PubMed · Cited by 143
Polsky, D., Bastian, B. C., Hazan, C., Melzer, K., Pack, J., Houghton, A., BUSAM, K. J., Cordon‐Cardo, C., & Osman, I. (2001) · PubMed · Cited by 142
Bode‐Lesniewska, B., Zhao, J., Speel, E. M., Biraima, A., Turina, M. I., Komminoth, P., & Heitz, P. U. (2001) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280000313 · Cited by 140 · cited 1×
“…75% Maybe worse 8 [195] Sarcoma (various) >33% n/a 47 [194] Sarcoma (various) 8% n/a 40 [8] Sarcoma 10% Worse 30 [64] Synovial sarcoma 59% n/a 49 [196] Blood cell cancers Leukemia (ALL, AML, B-CLL) 70% Worse 34 [74] Leukemia (ALL) 29% Worse 42 [29] Leukemia (ALL) 67% Worse 45 [73] Leukemia…”
Similar outcome of elderly patients in Intergroup Trial 0096
Yuen, A. R., Zou, G., Turrisi, A. T., Sause, W. T., Komaki, R. R., Wagner, H., Aisner, S. C., Livingston, R. B., Blum, R. H., & Johnson, D. H. (2000) · Cancer · doi:10.1002/1097-0142(20001101)89:9<2006::aid-cncr18>3.0.co;2-7 · Cited by 140
Higashiyama, M., Doi, O., Kodama, K., Yokouchi, H., Kasugai, T., Ishiguro, S., Takami, K., Nakayama, T., & Nishisho, I. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.221 · Cited by 133
Owen, J. D., Strieter, R., Burdick, M., Haghnegahdar, H., Nanney, L., Shattuck-Brandt, R., & Richmond, A. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970926)73:1<94::aid-ijc15>3.0.co;2-5 · Cited by 133
Inactivation of the p53 pathway in prostate cancer: impact on tumor progression.
Osman, I., Drobnjak, M., Fazzari, M. J., Ferrara, J., Scher, H. I., & Cordon‐Cardo, C. (1999) · PubMed · Cited by 131
Petrilli, A. S., Dantas, L. S., Campos, M. C., Tanaka, C., Ginani, V. C., & Seber, A. (2000) · Medical and Pediatric Oncology · doi:10.1002/(sici)1096-911x(200002)34:2<87::aid-mpo2>3.0.co;2-f · Cited by 131
Gu, L., Findley, H. W., & Zhou, M. (2002) · Blood · doi:10.1182/blood.v99.9.3367 · Cited by 127 · cited 1×
“One group noted that this type of induction overcame the pro-apoptotic effects of p53, leading to resistance to doxorubicin [98].”
BackgroundMcCann, A., Kirley, A., Carney, D., Corbally, N., Magee, H., Keating, G., & Dervan, P. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.189 · Cited by 126 · cited 2×
“Up to 54% positive staining was seen by one group [48], and gene amplification was observed in 4% to 61% of tumor samples [49] [50] [51] [52] [53] [54] [55].”
BackgroundNakayama, T., Toguchida, J., Wadayama, B., Kanoe, H., Kotoura, Y., & Sasaki, M. S. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640511 · Cited by 122
Clinicopathological and immunohistochemical analysis of twenty-five head and neck osteosarcomas
Takahama, A., Alves, F. D. A., Pinto, C. A. L., Carvalho, A. L., Kowalski, L. P., & Lopes, M. A. (2003) · Oral Oncology · doi:10.1016/s1368-8375(03)00017-4 · Cited by 122 · cited 1×
“…94 [192] Soft tissue sarcoma 21% Maybe better 72 [69] Soft tissue sarcoma 28% 54% Maybe better 71 [68] Uterine sarcoma 50% 33% No correlation 12 [190] Angiosarcoma (vascular) 68% Maybe worse 19 [9] Intimal Sarcoma (pulmonary artery) 75% Maybe worse 8 [195] Sarcoma (various) >33% n/a 47 [194]…”
BackgroundBurton, E., Lamborn, K. R., Forsyth, P. A., Scott, J. N., O’Campo, J., Uyehara‐Lock, J. H., Prados, M. D., Berger, M. S., Passe, S. M., Uhm, J. H., et al. (2002) · PubMed · Cited by 119
Abnormal Expression of MDM2 in Prostate Carcinoma
Leite, K. R. M., de Franco, M. F., Srougi, M., Nesrallah, L., Nesrallah, A., Bevilacqua, R. G., Darini, E., Carvalho, C. M., Meirelles, M. I., Santana, I., et al. (2001) · Modern Pathology · doi:10.1038/modpathol.3880330 · Cited by 115 · cited 1×
“One group found that overexpression of the oncoprotein is associated with advanced stage disease, whereas another found that tumors expressing the protein have a higher proliferation index and larger tumor volume [82] [83].”
BackgroundEymin, B., Gazzéri, S., Brambilla, C., & Brambilla, E. M. (2002) · Oncogene · doi:10.1038/sj.onc.1205359 · Cited by 114
Gorgoulis, V. G., Zacharatos, P., Kotsinas, A., Liloglou, T., Kyroudi, A., Veslemes, M., Rassidakis, A., Halazonetis, T. D., Field, J. K., & Kittas, C. N. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65690-8 · Cited by 113 · cited 1×
“Up to 27% of NSCLC expressed this combination (abnormal pRb, overexpressed p53 and MDM2), and these tumors had a higher proliferation index, lower apoptotic index and an increased tendency to aneuploidy compared to tumors with normal expression [108] [128].”
BackgroundRegulation of p53 Stability and Function in HCT116 Colon Cancer Cells
Kaeser, M. D., Pebernard, S., & Iggo, R. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311732200 · Cited by 112
MDM2 Oncogene as a Novel Target for Human Cancer Therapy
Zhang, R., & Wang, H. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003400911 · Cited by 111
Self-citationZhang, L., & Hill, R. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3038 · Cited by 107 · cited 2×
“This overexpression leads to an increased metastatic efficiency in cell lines, perhaps by rendering tumor cells less sensitive to stressinduced cell death [86].”
Backgroundmdm2 gene alterations and mdm2 protein expression in breast carcinomas
Marchetti, A., Buttitta, F., Girlando, S., Palma, P. D., Pellegrini, S., Fina, P., Doglioni, C., Bevilacqua, G., & Barbareschi, M. (1995) · The Journal of Pathology · doi:10.1002/path.1711750106 · Cited by 103
Korkolopoulou, P. A., Christodoulou, P. N., Kapralos, P., Exarchakos, M., Bisbiroula, A., Hadjiyannakis, M., Georgountzos, C., & Thomas-Tsagli, E. (1997) · Pathology - Research and Practice · doi:10.1016/s0344-0338(97)80055-6 · Cited by 100
MDM2 and CDK4 gene amplification in Ewing's sarcoma
Ladanyi, M., Lewis, R., Jhanwar, S. C., Gerald, W., Huvos, A. G., & Healey, J. H. (1995) · The Journal of Pathology · doi:10.1002/path.1711750209 · Cited by 98 · cited 1×
“There have been several studies indicating that MDM2 overexpression correlates with a worse prognosis [63] [64] [65].”
BackgroundOncogene Amplification in Urothelial Cancers With p53 Gene Mutation or MDM2 Amplification
Habuchi, T., Kinoshita, H., Yamada, H., Kakehi, Y., Ogawa, O., Wu, W.-J., Takahashi, R., Sugiyama, T., & Yoshida, O. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.17.1331 · Cited by 96 · cited 1×
“…Bladder 5% n/a 2317 [46] Bladder 12% Worse 119 [41] Bladder 46% Worse 140 [53] Pancreatic 64% Maybe better 167 [177] Wilm's tumor (kidney) 0% n/a 11 [186] Cervix 0% n/a 27 [162] Cervix 50% No correlation 178 [163] Cervix 2% n/a 43 [164] Prostate 41% Worse 118 [82] Prostate 33% Worse 86 [81]…”
Zhou, M., Gu, L., Abshire, T. C., Homans, A., Billett, A. L., Yeager, A., & Findley, H. W. (2000) · Leukemia · doi:10.1038/sj.leu.2401619 · Cited by 95 · cited 3×
“Acute lymphocytic leukemia (ALL) has more than 10-fold overexpression of MDM2 protein in more than 29% of samples [30] [31].”
BackgroundMDM2 gene amplification correlates with ring chromosomes in soft tissue tumors
Nilbert, M. C., Mitelman, F., Mandahl, N., Rydholm, A., & Willén, H. (1994) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870090406 · Cited by 95
Dong, Y., Sui, L., Sugimoto, K., Tai, Y., & Tokuda, M. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010720)95:4<209::aid-ijc1036>3.0.co;2-r · Cited by 93
Alterations of Cell Cycle Regulators in Localized Synovial Sarcoma
Antonescu, C. R., Leung, D. H. Y., Dudas, M. E., Ladanyi, M., Brennan, M. F., Woodruff, J. M., & Cordon‐Cardo, C. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64965-6 · Cited by 92
Clinical Trials of Adenoviruses in Brain Tumors: A Review of Ad-p53 and Oncolytic Adenoviruses
Vecil, G. G., & Lang, F. F. (2003) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000003653.45635.32 · Cited by 90
Sengupta, S., & Wasylyk, B. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1321.005 · Cited by 89 · cited 2×
“The protein may act similarly for the estrogen, androgen and glucocorticoid receptors, influencing their stability by increasing their ubiquitination [116] [117].”
BackgroundScott, C., Nelson, J. S., Farnan, N. C., Curran, W. J., Murray, K. J., Fischbach, A. J., Gaspar, L. E., & Nelson, D. F. (1995) · Cancer · doi:10.1002/1097-0142(19950715)76:2<296::aid-cncr2820760221>3.0.co;2-l · Cited by 84
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Sjöström, J., BLOMQVIST, C. P., Heikkilä, P., von Boguslawski, K., Räisänen-Sokolowski, A. K., Bengtsson, N. O., Mjaaland, I., Malmström, P., Ostenstadt, B., Bergh, J. C. S., et al. (2000) · PubMed · Cited by 83
HDM2 Protein Overexpression and Prognosis in Primary Malignant Melanoma
Polsky, D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.23.1803 · Cited by 82
MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications
Agarwal, S., Mathur, M., Srivastava, A., & Ralhan, R. (1999) · Oral Oncology · doi:10.1016/s1368-8375(98)00092-x · Cited by 78
Analysis of Ki-ras, p53, and MDM2 Genes in Uterine Leiomyomas and Leiomyosarcomas
Hall, K. L., Teneriello, M. G., Taylor, R. R., Lemon, S. J., Ebina, M., Linnoila, R. I., Norris, J. H., Park, R. C., & Birrer, M. J. (1997) · Gynecologic Oncology · doi:10.1006/gyno.1997.4653 · Cited by 77 · cited 1×
“…sarcoma 38% 18% Maybe better 94 [70] Soft tissue sarcoma 37% Worse 211 [63] Soft tissue sarcoma 24% n/a 67 [13] Soft tissue sarcoma 21% Worse 94 [192] Soft tissue sarcoma 21% Maybe better 72 [69] Soft tissue sarcoma 28% 54% Maybe better 71 [68] Uterine sarcoma 50% 33% No correlation 12 [190]…”
BackgroundMori, S., Ito, G., Usami, N., Yoshioka, H., Ueda, Y., Kodama, Y., Takahashi, M., Fong, K. M., Shimokata, K., & Sekido, Y. (2004) · Cancer · doi:10.1002/cncr.20164 · Cited by 76
Combined analysis of p53 and RB pathways in epithelial ovarian cancer
Hashiguchi, Y., Tsuda, H., Yamamoto, K., Inoue, T., Ishiko, O., & Ogita, S. (2001) · Human Pathology · doi:10.1053/hupa.2001.27115 · Cited by 76 · cited 1×
“Ovarian 57% Maybe better 46 [178] Ovarian 17% No correlation 46 [179] Ovarian 12%-41% No correlation 90 [180] Ovarian 13% No correlation 347 [181] Ovarian 3% n/a 43 [182] Ovarian Positive n/a 10 [183] Bladder 18% n/a 88 [45] Bladder positive Worse 80 [77] Bladder 20% no correlation 50 [44] Bladder…”
BackgroundNishizaki, M., Sasaki, J.-I., Fang, B., Atkinson, E. N., Minna, J. D., Roth, J. A., & Ji, L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0195 · Cited by 75
Dorota Dworakowska, B., Jassem, E., Jassem, J., Peters, B., Dziadziuszko, R., Żylicz, M., Jakóbkiewicz‐Banecka, J., Kobierska‐Gulida, G., Szymanowska, A., Skokowski, J., et al. (2003) · Lung Cancer · doi:10.1016/j.lungcan.2003.09.010 · Cited by 73
p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix.
Kessis, T. D., Slebos, R. J. C., Han, S. M., Shah, K. V., Bosch, X. F., Muñóz, N., Hedrick, L., & Cho, K. R. (1993) · PubMed · Cited by 73
Marchetti, A., Buttitta, F., Pellegrini, S., Merlo, G., Chella, A., Angeletti, C. A., & Bevilacqua, G. (1995) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199506000-00004 · Cited by 71
Datta, M. W., Macrì, E., Signoretti, S., Renshaw, A. A., & Loda, M. F. (2001) · Modern Pathology · doi:10.1038/modpathol.3880331 · Cited by 70
Guenther, T., Schneider‐Stock, R., Häckel, C., Kasper, H., Pross, M., Hackelsberger, A., Lippert, H., & Roessner, A. (2000) · Modern Pathology · doi:10.1038/modpathol.3880107 · Cited by 69
Kinney, A. Y., Vernon, S. W., Frankowski, R. F., Weber, D. M., Bitsura, J. M., & Vogel, V. G. (1995) · Cancer · doi:10.1002/1097-0142(19950701)76:1<96::aid-cncr2820760114>3.0.co;2-e · Cited by 68
Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma
Takahashi, Y., Oda, Y., Kawaguchi, K.-I., Tamiya, S., Yamamoto, H., Suita, S., & Tsuneyoshi, M. (2004) · Modern Pathology · doi:10.1038/modpathol.3800101 · Cited by 67 · cited 2×
“There have been several studies indicating that MDM2 overexpression correlates with a worse prognosis [63] [64] [65].”
BackgroundOsman, I., Sherman, E. J., Singh, B., Venkatraman, E. S., Zeléfsky, M. J., Bosl, G. J., Scher, H. I., Shah, J. P., Shaha, A. R., Kraus, D. H., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.161 · Cited by 67
p53 and MDM2 in the Development and Progression of Bladder Cancer
Ackermann, R., Schmitz-Dräger, B. J., Kushima, M., Goebell, P., Jax, T. W., Gerharz, C.-D., Bültel, H., Schulz, W. A., & Ebert, T. (1997) · European Urology · doi:10.1159/000480813 · Cited by 66
Analysis of mdm2 and p53 Gene Alterations in Glioblastomas and its Correlation with Clinical Factors
Schiebe, M., Ohneseit, P., Hoffmann, W., Meyermann, R., Rodemann, H. P., & Bamberg, M. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1006410702284 · Cited by 63 · cited 3×
“Glioblastomas and astrocytomas show positive staining for MDM2 protein in up to 75% of tumor samples, and approximately 10% of samples have gene amplification [20] [21] [22] [23] [24] [25] [26] [27] [28] [29].”
BackgroundReid, A. H., Tsai, M. M., Venzon, D. J., Wright, C. F., Lack, E. E., & O’Leary, T. J. (1996) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199603000-00010 · Cited by 61 · cited 1×
“…12 [190] Angiosarcoma (vascular) 68% Maybe worse 19 [9] Intimal Sarcoma (pulmonary artery) 75% Maybe worse 8 [195] Sarcoma (various) >33% n/a 47 [194] Sarcoma (various) 8% n/a 40 [8] Sarcoma 10% Worse 30 [64] Synovial sarcoma 59% n/a 49 [196] Blood cell cancers Leukemia (ALL, AML, B-CLL) 70%…”
Yanamoto, S., Kawasaki, G., Yoshitomi, I., & Mizuno, A. (2002) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1067/moe.2002.127404 · Cited by 59
MDM2 Mediated Nuclear Exclusion of p53 Attenuates Etoposide-Induced Apoptosis in Neuroblastoma Cells
Rodríguez-López, A. M., Xenaki, D., Eden, T. O. B., Hickman, J. A., & Chresta, C. M. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.1.135 · Cited by 58 · cited 1×
“In neuroblastoma cells, high levels of MDM2 led to an increase in the degradation of p53 and resulted in resistance to etoposide-induced apoptosis [90].”
BackgroundRetinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia
Chen, Z., Tong, J., Dong, S., Zhu, J., Wang, Z., & Chen, S. (1996) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199603)15:3<187::aid-gcc8>3.0.co;2-z · Cited by 57
Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer
Mathew, R., Arora, S., Khanna, R., Mathur, M., Shukla, N. K., & Ralhan, R. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00007-2 · Cited by 57 · cited 1×
“Examination of 100 samples of esophageal squamous cell carcinoma found that MDM2 expression was the most significant risk factor for distant metastasis [84].”
BackgroundExpression of heparanase, Mdm2, and erbB2 in ovarian cancer
Ginath, S., Menczer, J., Friedmann, Y., Aingorn, H., Aviv, A., Tajima, K., Dantes, A., Glezerman, M., Vlodavsky, I., & Amsterdam, A. (2001) · International Journal of Oncology · doi:10.3892/ijo.18.6.1133 · Cited by 57 · cited 1×
“22% n/a 45 [61] Esophageal adenocarcinoma 55% 0% n/a 33 [165] Thyroid 2-3 fold n/a 20 [184] Larynx & pharynx 74% Worse 70 [187] Breast 13%-21% Worse 38 [52] Breast 44%-56% n/a 54 [47] Breast 14% 8% No correlation 52 [50] Breast 7% 4% Maybe worse 82 [48] Breast 10% n/a 239 [51] Breast (IDC/DCIS) 89%…”
Eerola, A., Törmänen, U., Rainio, P., Sormunen, R. T., Bloigu, R., Vähäkangas, K., Lehto, V., Soini, Y., & Pääkkö, P. K. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199702)181:2<172::aid-path715>3.0.co;2-2 · Cited by 56
Shibagaki, I., Tanaka, H., Shimada, Y., Wagata, T., Ikenaga, M., Imamura, M., & Ishizaki, K. (1995) · PubMed · Cited by 55
Skomedal, H., Kristensen, G. B., Abeler, V. M., Børresen‐Dale, A., Tropé, C., & Holm, R. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199702)181:2<158::aid-path742>3.0.co;2-8 · Cited by 55 · cited 1×
“…better 46 [178] Ovarian 17% No correlation 46 [179] Ovarian 12%-41% No correlation 90 [180] Ovarian 13% No correlation 347 [181] Ovarian 3% n/a 43 [182] Ovarian Positive n/a 10 [183] Bladder 18% n/a 88 [45] Bladder positive Worse 80 [77] Bladder 20% no correlation 50 [44] Bladder 18%-49% no…”
BackgroundWang, H., Oliver, P. G., Zhang, Z., Agrawal, S., & Zhang, R. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1281.025 · Cited by 54 · cited 2×
“To confirm this hypothesis, we have recently used antisense or small interfering RNA (siRNA) to knock down MDM2 expression and have demonstrated that inhibition of MDM2 resulted in chemosensitization and radiosensitization in various human cancer models [99].”
BackgroundMethodSelf-citationAltered Expression of G1 Regulatory Proteins in Human Soft Tissue Sarcomas
Yoo, J., Park, S. Y., Kang, S. J., Shim, S. I., & Kim, B. K. (2002) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2002-126-0567-aeogrp · Cited by 54
Faderl, S., Kantarjian, H. M., Estey, E., Manshouri, T., Chan, C.-Y., Rahman Elsaied, A., Kornblau, S. M., Cortes, J., Thomas, D. A., Pierce, S., et al. (2000) · Cancer · doi:10.1002/1097-0142(20001101)89:9<1976::aid-cncr14>3.0.co;2-n · Cited by 52
Wang, H., Nan, L., Yu, D., Lindsey, J. R., Agrawal, S., & Zhang, R. (2002) · Molecular Medicine · doi:10.1007/bf03402011 · Cited by 50
Self-citationBianco, R., Caputo, R., Caputo, R., Damiano, V., Placido, S. D., Ficorella, C., Agrawal, S., Bianco, A. R., Ciardiello, F., & Tortora, G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0497 · Cited by 49
Møller, M. B., Nielsen, O., & Pedersen, N. T. (1999) · PubMed · Cited by 48
Węsierska‐Gądek, J., & HORKYA, M. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1299.046 · Cited by 48
MDM2 overexpression is associated with short survival in adults with medulloblastoma
Giordana, M. T., Duó, D., Gasverde, S., Trevisan, E., Boghi, A., Morra, I., Pradotto, L., Mauro, A., & Chiò, A. (2002) · Neuro-Oncology · doi:10.1093/neuonc/4.2.115 · Cited by 48
Amplification and protein expression of chromosome 12q13-15 genes in osteosarcomas of the jaws
Lopes, M. A., Nikitakis, N. G., Ord, R. A., & Sauk, J. J. (2001) · Oral Oncology · doi:10.1016/s1368-8375(00)00130-5 · Cited by 48
The Organization and Expression of themdm2Gene
Luna, R. M. D. O., Tabor, A., Eberspaecher, H., Hulboy, D. L., Worth, L. L., Colman, M. S., Finlay, C. A., & Lozano, G. (1996) · Genomics · doi:10.1006/geno.1996.0210 · Cited by 47
Amplification and Overexpression of mdm2 Gene in Ependymomas
Suzuki, S. O., & Iwaki, T. (2000) · Modern Pathology · doi:10.1038/modpathol.3880095 · Cited by 47 · cited 1×
“…30% Worse 62 [35] Lymphoma (non-Hodgkin's) 22% Worse 188 [36] Lymphoma (non-Hodgkin's) 60% Worse 188 [37] Lymphoma (non-Hodgkin's) 87% Worse 15 [38] Lymphoma (non-Hodgkin's) 80% Worse 42 [39] Multiple myeloma 58% 0% n/a 48 [160] for cancer patients, with respect to diagnosis and prognosis.”
BackgroundHori, M., Shimazaki, J., Inagawa, S., Itabashi, M., & Hori, M. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1013350419426 · Cited by 45 · cited 3×
“Hori and colleagues found that MDM2 expression correlated with estrogen receptor status, occurring only in estrogen receptorα (ER-α) positive tumors [79].”
BackgroundHorie, S., Endo, K., Kawasaki, H., & Terada, T. (2000) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280000201 · Cited by 45 · cited 1×
“Another found that MDM2 splice variants analyzed in 60 breast cancer samples generally were associated with more aggressive cancer and more frequent involvement of axillary lymph nodes [85].”
BackgroundRole of MDM2 Overexpression in Doxorubicin Resistance of Breast Carcinoma
Suzuki, A., Toi, M., Yamamoto, Y., Saji, S., Muta, M., & Tominaga, T. (1998) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1998.tb00552.x · Cited by 44 · cited 1×
“A similar study using transfected MCF-7 cells gave a 3-fold increase in resistance to doxorubicin in the presence of wild-type p53 [89].”
BackgroundMDM2 expression during mouse embryogenesis and the requirement of p53
Léveillard, T., Gorry, P., Niederreither, K., & Wasylyk, B. (1998) · Mechanisms of Development · doi:10.1016/s0925-4773(98)00074-4 · Cited by 43
Elkablawy, M. A., Maxwell, P., Williamson, K. E., Anderson, N., & Hamilton, P. W. (2001) · The Journal of Pathology · doi:10.1002/path.894 · Cited by 42 · cited 3×
“Studies using breast and colorectal tumors revealed that those positive for MDM2, p53 and p21, or MDM2, bcl-2 and p21 had a more favorable prognosis than those with decreased p21 [58] [110].”
BackgroundMDM2/p53 protein expression in the development of colorectal adenocarcinoma
Abdel‐Fattah, G., Yoffe, B., Krishnan, B., Khaoustov, V. I., & Itani, K. M. F. (2000) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(00)80041-4 · Cited by 42 · cited 2×
“…Worse 32 [15] Testicular germ cell 7%-93% Worse 31 [16] Colon 65% n/a 52 [57] Colorectal 25% No correlation 52 [55] Colorectal 25% No correlation 55 [56] Melanoma 6%-56% 1% Maybe worse 172 [174] Melanoma 75% Better 134 [175] Sarcomas Uterine leiomyosarcoma 13% n/a 23 [191] Leiomyosarcoma 38% 8%…”
Backgroundmdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line
Kondo, S., Kondo, Y., Hara, H., Kaakaji, R., Peterson, J. W., Morimura, T., Takeuchi, J., & Barnett, G. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.527 · Cited by 41 · cited 2×
“HER-2 activates Akt, which in turn activates MDM2, increasing the degradation of p53 and the resistance to chemotherapy and radiation [95].”
BackgroundGorgoulis, V. G., Zacharatos, P., Kotsinas, A., Mariatos, G., Liloglou, T., Vogiatzi, T., Foukas, P., Rassidakis, G., Garinis, G., Ioannides, T., et al. (2000) · Molecular Medicine · doi:10.1007/bf03402115 · Cited by 40
MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status
Foulkes, W., Stamp, G., Afzal, S., Lalani, N., McFarlane, C., Trowsdale, J., & Campbell, I. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.428 · Cited by 39 · cited 1×
“…No correlation 46 [179] Ovarian 12%-41% No correlation 90 [180] Ovarian 13% No correlation 347 [181] Ovarian 3% n/a 43 [182] Ovarian Positive n/a 10 [183] Bladder 18% n/a 88 [45] Bladder positive Worse 80 [77] Bladder 20% no correlation 50 [44] Bladder 18%-49% no correlation 92 [43] Bladder 38%…”
Backgroundmdm2 mRNA expression is associated with survival in ovarian cancer
Tanner, B., Hengstler, J. G., Laubscher, S., Meinert, R., Oesch, F., Weikel, W., Knapstein, P. G., & Becker, R. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970822)74:4<438::aid-ijc13>3.0.co;2-5 · Cited by 39
Expression profile of MDM-2 proteins in chronic lymphocytic leukemia and their clinical relevance
Haidar, M. A., El-Hajj, H., Bueso-Ramos, C., Manshouri, T., Glassman, A. B., Keating, M. J., & Albitar, M. X. (1997) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199703)54:3<189::aid-ajh3>3.0.co;2-s · Cited by 38
Intracellular ribozyme applications
Castanotto, D., Li, J. R., Michienzi, A., Langlois, M., Lee, N. S., Puymirat, J., & Rossi, J. J. (2002) · Biochemical Society Transactions · doi:10.1042/bst0301140 · Cited by 38
Manipulation of the tumor suppressor p53 for potentiating cancer therapy
Haupt, S. M., & Haupt, Y. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.04.003 · Cited by 38 · cited 1×
“…56 [25] Brain (glioblastoma) 13% Worse 75 [26] Brain (cerebellar medulloblastoma) 20% none Maybe worse 51 [27] Brain (GBM) positive n/a 143 [28] Ependymoma 96% 35% n/a 20 [159] Intracranial germ cell 81% 19% n/a 16 [17] Nasopharyngeal carcinoma 10-12 fold n/a 46 [176] Esophageal squamous cell car.”
Mu, Z., Hachem, P., Agrawal, S., & Pollack, A. S. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.029 · Cited by 36
Amplification of the mdm2 gene and p53 abnormalities in uterine sarcomas
Seki, A., Kodama, J., Miyagi, Y., Kamimura, S., Yoshinouchi, M., & Kudo, T. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970926)73:1<33::aid-ijc6>3.0.co;2-2 · Cited by 36
Qiu, S., Ye, S.-L., Wu, Z.-Q., Tang, Z., & Liu, Y.-K. (1998) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050162 · Cited by 35 · cited 1×
“MDM2 and p53 are only infrequently mutated within the same tumor [2] [8], and, although wild-type p53 increases MDM2 expression, many p53 mutants do not [26] [103] [75] [104].”
BackgroundThe expression of theMDM2 gene, a p53 binding protein, in thyroid carcinogenesis
Zou, M., Shi, Y., Al-Sedairy, S., Hussain, S. S., & Farid, N. R. (1995) · Cancer · doi:10.1002/1097-0142(19950715)76:2<314::aid-cncr2820760223>3.0.co;2-q · Cited by 34 · cited 1×
“…[53] Pancreatic 64% Maybe better 167 [177] Wilm's tumor (kidney) 0% n/a 11 [186] Cervix 0% n/a 27 [162] Cervix 50% No correlation 178 [163] Cervix 2% n/a 43 [164] Prostate 41% Worse 118 [82] Prostate 33% Worse 86 [81] Urothelial 4% n/a 50 [185] Urothelial carcinoma 23% Worse 60 [86] Verrucous Car.”
Koga, T., Hashimoto, S., Sugio, K., Yoshino, I., Nakagawa, K., Yonemitsu, Y., Sugimachi, K., & Sueishi, K. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010720)95:4<232::aid-ijc1040>3.0.co;2-5 · Cited by 34 · cited 1×
“…Breast 5% 7% Worse 137 [49] Breast 61% n/a 70 [54] Lung (adenocarcinoma) 4%-14% n/a 118 [169] Lung 18%-39% n/a 192 [108] Lung (NSCLC) 21% Worse 116 [170] Extrahepatic cholangiocarcinoma 61% n/a 13 [166] Intrahepatic cholangiocarcinoma 38% Worse 47 [84] Hepatoblastoma 0% n/a 19 [167] Liver…”
Oda, Y., Takahira, T., Kawaguchi, K., Yamamoto, H., Tamiya, S., Matsuda, S., Tanaka, K., Kinukawa, N., Iwamoto, Y., & Tsuneyoshi, M. (2003) · Human Pathology · doi:10.1053/s0046-8177(03)00404-0 · Cited by 33 · cited 2×
“tissue sarcomas found no correlation between MDM2 and overall survival, tumor grade or tumor origin [72] [73]. more easily treated and have better response rates than hormone-independent cancers.”
BackgroundHorie, S., Maeta, H., Endo, K., Ueta, T., TAKASHIMA, K., & Terada, T. (2001) · Pathology International · doi:10.1046/j.1440-1827.2001.01159.x · Cited by 32 · cited 1×
“This overexpression correlated with larger tumor size [120].”
BackgroundPrognostic Value of Mdm2, p53 and p16 in Patients with Astrocytomas
Ranuncolo, S. M., Varela, M. S., Morandi, A., Lastiri, J. M., Christiansen, S. B., Joffé, E. B. D. K., Pallotta, M. G., & Puricelli, L. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000027741.19213.99 · Cited by 32 · cited 3×
“Glioblastomas and astrocytomas show positive staining for MDM2 protein in up to 75% of tumor samples, and approximately 10% of samples have gene amplification [20] [21] [22] [23] [24] [25] [26] [27] [28] [29].”
BackgroundÖzdemir, E., Kakehi, Y., Okuno, H., Habuchi, T., Okada, Y., & Yoshida, O. (1997) · The Journal of Urology · doi:10.1097/00005392-199707000-00072 · Cited by 32 · cited 1×
“MDM2 expression also increases basement membrane degradation in urothelial carcinoma [87], allowing the cancer to spread.”
BackgroundDellas, A., Schultheiss, E., Almendral, A. C., Gudat, F. G., Oberholzer, M., Feichter, G. E., Moch, H., & Torhorst, J. K. H. (1997) · International Journal of Cancer · Cited by 32
Gustafsson, B. M., Axelsson, B., Gustafsson, B., Christensson, B., & Winiarski, J. H. (2001) · Pediatric Hematology and Oncology · doi:10.1080/088800101753328466 · Cited by 31 · cited 3×
“Expression of both molecules also was associated with a higher risk of relapse [74].”
BackgroundTP53 Mutations and mdm2 Protein Overexpression in Cholangiocarcinomas
Torre, G. D., Pasquini, G., Pilotti, S., Alasio, L. M., Civelli, E. M., Cozzi, G., Milella, M., Salvetti, M., Pierotti, M. A., & Severini, A. (2000) · Diagnostic Molecular Pathology · doi:10.1097/00019606-200003000-00007 · Cited by 31
Cocker, H. A., Hobbs, S., Tiffin, N., Pritchard‐Jones, K., Pinkerton, R., & Kèlland, L. R. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2145 · Cited by 30 · cited 2×
“increase resistance to cisplatin [88].”
BackgroundAge-related Expression of p53, Mdm2, EGFR and Msh2 in Glioblastoma Multiforme
Stark, A. M., Hugo, H., Witzel, P., Mihajlovic, Z., & Mehdorn, H. M. (2003) · Central European Neurosurgery - Zentralblatt für Neurochirurgie · doi:10.1055/s-2003-37149 · Cited by 30 · cited 3×
“Glioblastomas and astrocytomas show positive staining for MDM2 protein in up to 75% of tumor samples, and approximately 10% of samples have gene amplification [20] [21] [22] [23] [24] [25] [26] [27] [28] [29].”
BackgroundResultExpression of p53 and mdm2 and Their Significance in Recurrence of Superficial Bladder Cancer
Tuna, B., Yörükoğlu, K., Tüzel, E., Güray, M., Mungan, U., & Kırkalı, Z. (2003) · Pathology - Research and Practice · doi:10.1078/0344-0338-00424 · Cited by 30 · cited 1×
“One research group noted that MDM2 overexpression correlated with increased grade of tumors and was an indicator for future recurrence [78].”
BackgroundAmplification ofcyclin D1andMDM-2in oesophageal carcinoma
Morgan, R. J., Newcomb, P. V., Hardwick, R. H., & Alderson, D. (1999) · European Journal of Surgical Oncology · doi:10.1053/ejso.1999.0658 · Cited by 29 · cited 2×
“Esophageal squamous cell carcinomas had staining in about the same range [59] [60] and gene amplification in approximately 20% of tumor samples [61] [62].”
BackgroundIkenberg, H., Matthay, K., Schmitt, B., Bauknecht, T., Kiechle‐Schwarz, M., Göppinger, A., & Pfleiderer, A. (1995) · Cancer · doi:10.1002/1097-0142(19950701)76:1<57::aid-cncr2820760108>3.0.co;2-4 · Cited by 28
Immunohistochemical expression of Mdm2 and p53 in penile verrucous carcinoma.
Ouban, A., Dellis, J., Salup, R. R., & Morgan, M. (2003) · PubMed · Cited by 27
Würl, P., Meye, A., Berger, D., Bache, M., Lautenschläger, C., Schmidt, H., Kalthoff, H., Rath, F. W., & Taubert, H. W. (1997) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199710000-00001 · Cited by 27 · cited 3×
“The relative risk for death caused by soft tissue sarcomas was higher for patients with MDM2+/p53+ tumors than the additive risk from each factor alone [122].”
BackgroundIoachim, E. E., Charchanti, A. V., Stavropoulos, N. E., Skopelitou, A. S., Athanassiou, E. D., & Agnantis, N. J. (2000) · PubMed · doi:10.14670/hh-15.721 · Cited by 26 · cited 2×
“…20% no correlation 50 [44] Bladder 18%-49% no correlation 92 [43] Bladder 38% Maybe worse 106 [20] Bladder 30% 1% n/a 87 [42] Bladder 5% n/a 2317 [46] Bladder 12% Worse 119 [41] Bladder 46% Worse 140 [53] Pancreatic 64% Maybe better 167 [177] Wilm's tumor (kidney) 0% n/a 11 [186] Cervix 0% n/a…”
BackgroundEhrmann, J., Kolář, Z., Vojtěšek, B., Kala, M., Komenda, S., & Oulton, A. (1997) · PubMed · Cited by 26
Uchida, Τ., Minei, S., Gao, J.-P., Wang, C., Satoh, T., & Baba, S. (2002) · Oncology Reports · doi:10.3892/or.9.2.253 · Cited by 25 · cited 3×
“…Worse 80 [77] Bladder 20% no correlation 50 [44] Bladder 18%-49% no correlation 92 [43] Bladder 38% Maybe worse 106 [20] Bladder 30% 1% n/a 87 [42] Bladder 5% n/a 2317 [46] Bladder 12% Worse 119 [41] Bladder 46% Worse 140 [53] Pancreatic 64% Maybe better 167 [177] Wilm's tumor (kidney) 0%…”
BackgroundAltered expression of p53 and MDM2 proteins in hematological malignancies.
Koníková, E., & Kusenda, J. (2003) · PubMed · Cited by 24
Leuschner, I., Langhans, I., Schmitz, R., Harms, D., Mattke, A. C., & Treuner, J. (2003) · Pediatric and Developmental Pathology · doi:10.1007/s10024-001-0097-z · Cited by 24
Ikeguchi, M., Ueda, T., Fukuda, K., Yamaguchi, K., Tsujitani, S., & Kaibara, N. (2002) · American Journal of Clinical Oncology · doi:10.1097/00000421-200210000-00006 · Cited by 24 · cited 4×
“They found that MDM2 expression correlated with shorter survival for patients undergoing post-operative chemo-or radiotherapy [60].”
BackgroundInfluentialmdm-2 expression in human testicular germ-cell tumors and its clinical value.
Eid, H., Institóris, E., Géczi, L., Bodrogi, I., & Bak, M. (1999) · PubMed · Cited by 23
Cell cycle regulators in multiple myeloma: Prognostic implications of p53 nuclear accumulation
Pruneri, G., Carboni, N., Baldini, L., Intini, D., Colombi, M., Bertolini, F., Valentini, S., Maisonneuve, P., Viale, G., & Neri, A. (2003) · Human Pathology · doi:10.1053/hupa.2003.6 · Cited by 22
Molecular analysis for p53 and mdm2 in intracranial germ cell tumors
Iwato, M., Tachibana, O., Tohma, Y., Nitta, H., Hayashi, Y., & Yamashita, J. (2000) · Acta Neuropathologica · doi:10.1007/pl00007401 · Cited by 22
Saito, H., Tsujitani, S., Oka, S., Ideguchi, M., Maeta, M., & Kaibara, N. (2002) · Annals of Surgical Oncology · doi:10.1007/bf02557267 · Cited by 22 · cited 3×
“In addition, a few studies did not find a correlation between p53 and MDM2 expression and any prognostic factor [77] [122] [123]. that regulates cell cycle phase transition, likely through interactions with both p53 and MDM2 [106].”
BackgroundStefanou, D., Av, N., Agnantis, N. J., Athanassiadou, S., Briassoulis, E., & Pavlidis, N. (1998) · PubMed · Cited by 21
Røtterud, R., Berner, A., Holm, R., Skovlund, E., & Fosså, S. D. (2001) · British Journal of Urology · doi:10.1046/j.1464-410x.2001.02268.x · Cited by 21 · cited 1×
“Rotterud and colleagues noted no significant role for MDM2 in the radioresistance of tumors in 59 patients with transitional cell carcinoma of the bladder [92].”
BackgroundWürl, P., Meye, A., Berger, D., Lautenschläger, C., Bache, M., Holzhausen, H.-J., Schmidt, H., Dralle, H., Rath, F.-W., & Taubert, H. W. (1998) · Langenbeck s Archives of Surgery · doi:10.1007/s004230050099 · Cited by 21 · cited 2×
“Patients with tumors staining positive for both pRb and MDM2 had higher risk and a poorer prognosis than patients with overexpression of neither or only one factor [107].”
Backgroundmdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
Soslow, R. A., Altorki, N. K., Yang, G., Xie, D., & Yang, C. S. (1999) · PubMed · Cited by 21
Vestey, S., Sen, C., Calder, C., Perks, C., Pignatelli, M., & Winters, Z. (2004) · Breast Cancer Research · doi:10.1186/bcr912 · Cited by 20 · cited 3×
“Similar to reports on other cancers, several studies have found that MDM2 expression is predictive for worse clinical outcome and decreased survival in breast cancer patients [50] [54] [81].”
BackgroundResultMolecular control of the cell cycle in cancer: biological and clinical aspects.
Møller, M. B. (2003) · PubMed · Cited by 20
Elevated levels of MDM-2 and p53 expression are associated with high grade non-Hodgkin's lymphomas
Finnegan, M. C. M., Goepel, J. R., Royds, J. A., Hancock, B. W., & Goyns, M. H. (1994) · Cancer Letters · doi:10.1016/0304-3835(94)90081-7 · Cited by 20
Baccouche, S., Daoud, J., Frikha, M., Mokdad‐Gargouri, R., Gargouri, A. F., & JLIDI, R. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1299.136 · Cited by 20 · cited 4×
“Up to 54% positive staining was seen by one group [48], and gene amplification was observed in 4% to 61% of tumor samples [49] [50] [51] [52] [53] [54] [55].”
BackgroundInfluentialCellular expression of MDM2 and p53 in childhood leukemias with poor prognosis
Gustafsson, B. M., Gustafsson, B., Christenson, B., Gustafsson, B., Gustafsson, B., Hjalmar, V., & Winiarski, J. H. (2000) · Medical and Pediatric Oncology · Cited by 20
Expression of p53 and mdm2 mRNA and protein in colorectal carcinomas
Broll, R., Stark, A., Windhövel, U., Best, R., Strik, M. W., Schimmelpenning, H., Schwandner, O., Kujath, P., Bruch, H. ‐., & Duchrow, M. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00058-1 · Cited by 18 · cited 1×
“Other studies, involving squamous cell carcinoma of the lung and colorectal carcinoma, showed that co-expression of p53 and MDM2 was associated with increased lymph node metastases [118] [119].”
ResultAlterations in MDM2 expression in esophageal squamous cell carcinoma: Relationship with p53 status
Arora, S., Mathew, R., Mathur, M., Chattopadhayay, T. K., & Ralhan, R. (2001) · Pathology & Oncology Research · doi:10.1007/bf03032350 · Cited by 17
Expression of mdm2 and p53 in epithelial neoplasms of the colorectum
Hao, X., Gunther, T., Roessner, A., Price, A. B., & Talbot, I. C. (1998) · Molecular Pathology · doi:10.1136/mp.51.1.26 · Cited by 16 · cited 2×
“…14 [137] Testicular germ cell 12% n/a 25 [18] Testicular germ cell 56%-69% Worse 32 [15] Testicular germ cell 7%-93% Worse 31 [16] Colon 65% n/a 52 [57] Colorectal 25% No correlation 52 [55] Colorectal 25% No correlation 55 [56] Melanoma 6%-56% 1% Maybe worse 172 [174] Melanoma 75% Better 134…”
BackgroundA modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin
Tang, H.-J., Qian, D., Sondak, V. K., Stachura, S. V., & Lin, J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601653 · Cited by 15
Arany, I., Yen, A., & Tyring, S. K. (1997) · PubMed · Cited by 15
Mathoulin-Portier, M.-P., Viens, P., Cowen, D. M., Bertucci, F., Houvenaeghel, G. F., Geneix, J., Puig, B. C.-V. I., Bardou, V. J., & Jacquemier, J. D. (2000) · Oncology Reports · doi:10.3892/or.7.3.675 · Cited by 12 · cited 2×
“Studies using breast and colorectal tumors revealed that those positive for MDM2, p53 and p21, or MDM2, bcl-2 and p21 had a more favorable prognosis than those with decreased p21 [58] [110].”
BackgroundTaubert, H. W., Schuster, K., Brinck, U., Bartel, F., Kappler, M., Lautenschläger, C., Bache, M., Trump, C., Schmidt, H., Holzhausen, H.-J., et al. (2003) · Modern Pathology · doi:10.1097/01.mp.0000096045.51700.66 · Cited by 12
El-Kenawy, A. E.-M., El-kott, A. F., & Khalil, A. (2003) · The International Journal of Biological Markers · doi:10.5301/jbm.2008.2927 · Cited by 12 · cited 3×
“Bladder carcinomas, which have been well studied, display positive staining for MDM2 in 12% to 49% of tumors [21] [42] [43] [44] [45] [46].”
Background[Study of mdm2 gene amplification in primary breast tumors].
Fontana, X., Ferrari, P., Abbes, M., Monticelli, J., Namer, M., & Bussière, F. (1994) · PubMed · Cited by 11
Harlozinska, A., Bar, J. K., & Montenarh, M. (2000) · PubMed · Cited by 11
Paradiso, A., Ranieri, G., Simone, G., Silvestris, N., da Costa, A. C., Lena, M. D., Leone, A., Vallejo, C. T., & Lacava, J. A. (2002) · Oncology · doi:10.1159/000059576 · Cited by 8 · cited 1×
“Another study of colorectal cancer samples found no correlation between MDM2 expression and the response to chemotherapy [93].”
BackgroundRegulation of mdm2 mRNA expression in human breast tumor-derived GI-101A cells
Zell, J. A., Ramakrishnan, R., & Rathinavelu, A. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)02045-3 · Cited by 6 · cited 2×
“…n/a 54 [47] Breast 14% 8% No correlation 52 [50] Breast 7% 4% Maybe worse 82 [48] Breast 10% n/a 239 [51] Breast (IDC/DCIS) 89% Maybe better 103 [80] Breast 5% 7% Worse 137 [49] Breast 61% n/a 70 [54] Lung (adenocarcinoma) 4%-14% n/a 118 [169] Lung 18%-39% n/a 192 [108] Lung (NSCLC) 21% Worse…”
BackgroundMansouri, S. E., Martin, A., Mercadier, A., Capoulade, C., Maréchal, V., Wiels, J., Feuillard, J., & Raphaël, M. (1999) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215549904701011 · Cited by 6 · cited 1×
“E2F-1 is a transcription factor MDM2 is overexpressed in Epstein-Barr virus (EBV)infected cells [133] and the protein may be overexpressed upon human papilloma virus (HPV) infection [134].”
BackgroundCirrhotic livers reveal genetic changes in the MDM2-P14ARF system of cell cycle regulators
Schlott, T., Scharf, J., Gorzel, C., Middel, P., & Spring, H. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600238 · Cited by 6 · cited 1×
“…10% n/a 239 [51] Breast (IDC/DCIS) 89% Maybe better 103 [80] Breast 5% 7% Worse 137 [49] Breast 61% n/a 70 [54] Lung (adenocarcinoma) 4%-14% n/a 118 [169] Lung 18%-39% n/a 192 [108] Lung (NSCLC) 21% Worse 116 [170] Extrahepatic cholangiocarcinoma 61% n/a 13 [166] Intrahepatic cholangiocarcinoma…”
Zhang, J., Liu, H., Li, S., & Gu, C. (1999) · PubMed · Cited by 2
[Alterations of MDM2 and p53 genes in bone tumors].
Zhou, X., Gao, L., & Xu, Z. (1997) · PubMed · Cited by 1
Cited by
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571
The MDM2-p53 pathway revisited
Subhasree, N., Jiangjiang, Q., Kalkunte, S., Minghai, W., & Ruiwen, Z. (2013) · The Journal of Biomedical Research · doi:10.7555/jbr.27.20130030 · Cited by 414
“MDM2 overexpression also correlates with metastasis and advanced forms of the disease in osteosarcomas, and cancers of the colon, breast and prostate, and is often associated with more treatment resistant tumors([35]).”
BackgroundSelf-citationMolecular targeting therapies for neuroblastoma: Progress and challenges
Zafar, A., Wang, W., Liu, G., Wang, X., Xian, W., McKeon, F., Foster, J., Zhou, J., & Zhang, R. (2021) · Medicinal Research Reviews · doi:10.1002/med.21750 · Cited by 380
“In general, MDM2 overexpression in human cancers has been found to be correlated to a poor prognosis, and associates with metastasis and advanced stages of the disease.(102) The enhanced MDM2 activity leads to attenuation of p53 activity, and thus results in increased tumor formation.”
BackgroundSelf-citationTargeting the MDM2-p53 Interaction for Cancer Therapy
Shangary, S., & Wang, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5136 · Cited by 366
Metadata
- Authors
- Rayburn, E., Zhang, R., He, J., & Wang, H.
- Affiliations
- University of Alabama at Birmingham (US)
- Venue
- Current Cancer Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-02-01
- Volume
- 5
- Issue
- 1
- Pages
- 27-41
- ISSN
- 1568-0096 (ISSN-L)
- OpenAlex
- W2107368531
- Cited by
- 265
- References
- 172
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 8 · 2023: 15 · 2022: 10 · 2021: 13 · 2020: 15 · 2019: 18 · 2018: 12 · 2017: 24 · 2016: 10 · 2015: 20 · 2014: 19 · 2013: 13 · 2012: 12
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Cancer Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca080698-04)
- National Cancer Institute (R01CA112029, R01 CA 80698)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- MDM2, p53, oncogene overexpression, prognostic factors, metastasis, chemoresistance, diagnostic biomarkers, cancer drug targets, sarcoma, leukemia, solid tumors, tumor progression
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasm Metastasis, Neoplasms, Nuclear Proteins, Prognosis, Proto-Oncogene Proteins, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.